EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis

Samuel Yamshon, Caitlin Gribbin, Mohammad Alhomoud, Nora Chokr, Zhengming Chen, Michelle Demetres, Michelle Pasciolla, John Leonard, Tsiporah Shore, Peter Martin

Clinical Lymphoma Myeloma and Leukemia · 2024-06 · 24 (6) · e235-e256.e2

DOI: 10.1016/j.clml.2024.02.007 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-06. Verfasst von Samuel Yamshon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY. Electronic address: sjy9001@med.cornell.edu. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The application of CD19-directed chimeric antigen receptor T (CAR T) cell therapy has improved outcomes for thousands of patients with non-Hodgkin B cell lymphoma (NHL). The toxicities associated with various CAR T cell products, however, can be severe and difficult to anticipate. METHODS: In this systematic review and meta-analysis, we set out to determine whether there are measurable differences in common toxicities, including cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), cytopenias, and infections, between CAR T products that are commercially available for the treatment of NHL. RESULTS: After a stringent study selection process, we used a cohort of 1364 patients enrolled in 15 prospective clinical trials investigating the use of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). We found that the rates of CRS and ICANS were significantly higher with axi-cel as compared to both liso-cel and tisa-cel. Conversely, we demonstrated that rates of all-grade and severe neutropenia were significantly greater with liso-cel. Febrile neutropenia and all-grade infection rates did not differ significantly between products though rates of severe infection were increased with axi-cel. CONCLUSIONS: Overall, this study serves as the first to delineate toxicity profiles associated with various available CAR T products. By better understanding associated toxicities, it may become possible to tailor therapies towards individual patients and anticipate the development of toxicities at earlier stages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveLymphoma, Non-HodgkinHumansReceptors, Chimeric Antigen

Stichwörter der Autor:innen

CRSCellular therapyDiffuse large B-cell lymphomaFollicular lymphomaICANS

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY. Electronic address: sjy9001@med.cornell.edu.
  • Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY.
  • Division of Biostatistics and Epidemiology, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.
  • Samuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell Medicine, New York, NY.
  • Department of Pharmacy, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY.

Zitieren

APA

Yamshon, S., Gribbin, C., Alhomoud, M., Chokr, N., Chen, Z., Demetres, M., Pasciolla, M., Leonard, J., Shore, T., & Martin, P. (2024). Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia, 24(6), e235-e256.e2. https://doi.org/10.1016/j.clml.2024.02.007

Vancouver

Yamshon S, Gribbin C, Alhomoud M, Chokr N, Chen Z, Demetres M, et al. Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia. 2024;24(6):e235-e256.e2. doi:10.1016/j.clml.2024.02.007

BibTeX
@article{Yamshon2024,
  author = {Yamshon, Samuel and Gribbin, Caitlin and Alhomoud, Mohammad and Chokr, Nora and Chen, Zhengming and Demetres, Michelle and Pasciolla, Michelle and Leonard, John and Shore, Tsiporah and Martin, Peter},
  title = {Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  volume = {24},
  number = {6},
  pages = {e235--e256.e2},
  doi = {10.1016/j.clml.2024.02.007}
}
Kostenlos starten →